Palifermin reduces severe oral mucositis (OM), improves patient quality of life, and reduces health resource use in patients with hematologic malignancies receiving high-dose chemotherapy (HDCT) and total body irradiation (TBI) with autologous peripheral blood stem cell (PBSC) support: results from a phase III trial

✍ Scribed by W. Bensinger; D. Weisdorf; T. Gentile; A. Cesano; D. Elhardt; C. Emmanouilides; M.H. Erder; K. Hansen; J. Isitt; T. Kewalramani; J. McCarty; S. Noga; A. Rong; T. Shea; R. Spielberger; S. Yanovich; P. Stiff

• Book ID: 116277672
• Publisher: Elsevier Science
• Year: 2004
• Tongue: English
• Weight: 64 KB
• Volume: 10
• Category: Article
• ISSN: 1083-8791
• DOI: 10.1016/j.bbmt.2003.12.135